VRTXON

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation.

NimiVRTXON

KohtNo.3709

Turulagi$0.00

Täielikult lahjendatud turukapital$0.00

Turuosa%

Kauplemismaht/turukapital (24H)0.00%

Ringlev varu0.35953858

Maksimaalne varu0

Koguvaru0.35953858

Ringluse määr%

Väljaandmise kuupäev--

Hind, millega vara esmakordselt välja anti--

Kõigi aegade kõrgeim466.35223147502205,2026-03-26

Madalaim hind432.04959348516377,2026-03-27

Avalik plokiahelETH

TutvustusVertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation.

Sektor

Sotsiaalmeedia

• Ametlik veebisait
• Blokeerige Explorer

etfindex:mc_etfindex_sourceLahtiütlus: Andmed on esitanud cmc ja neid ei tohiks käsitleda investeerimisnõuannetena.